1 citations
,
April 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors are effective treatments for alopecia areata.
April 2024 in “Bioactive materials” New microneedle treatment with growth factors and a hair loss drug shows better and faster hair growth results than current treatments.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
November 2016 in “The Molecular Biology Society of Japan” April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
August 2023 in “International journal of research in dermatology” Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
June 2024 in “British Journal of Dermatology” KRT14 gene variants cause dermatopathia pigmentosa reticularis, affecting nails, teeth, and hair.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
3 citations
,
March 2024 in “Journal of the American Academy of Dermatology” Low-dose naltrexone helps improve symptoms and stabilize frontal fibrosing alopecia and lichen planopilaris.
April 2026 in “BioNanoScience” A new microneedle system may improve hair loss treatment by delivering ketoconazole directly to hair follicles.
48 citations
,
June 1988 in “PubMed” Minoxidil sulfate relaxes muscle by increasing potassium flow, making it a unique muscle relaxer.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
7 citations
,
April 2023 in “Frontiers in immunology” Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
4 citations
,
May 2025 in “Frontiers in Immunology” JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
July 2024 in “Journal of Investigative Dermatology” Brepocitinib improves cicatricial alopecia and reduces key immune markers.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
November 2025 in “Mendeley Data” JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.
6 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.
20 citations
,
July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Six existing drugs may help block virus entry in COVID-19.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
7 citations
,
March 2013 in “Tetrahedron Letters” New method makes important drug ingredients more easily without needing extra purification steps.
April 2023 in “Journal of Investigative Dermatology” A new treatment for hair loss shows promise with fewer side effects.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
88 citations
,
February 2008 in “Journal of Medicinal Chemistry” Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.
April 2015 in “The FASEB Journal” Midazolam's antiseizure effects are mainly due to synaptic GABA-A receptors, not neurosteroids or extrasynaptic receptors.
April 2023 in “Journal of Investigative Dermatology” CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.
December 2023 in “Melatonin research” Nanocarriers make melatonin more effective and reduce side effects.